close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Latus Bio, Inc.

News headline image
Latus Bio Announces Four Abstracts Selected for Presentation at the European Society of Gene and Cell Therapy 33rd Annual Congress
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio Announces New Data Presentation at American Society of Nephrology (ASN) Kidney Week 2026
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio Appoints Donald Hayden as Chairman of the Board and Michael MacLean as Independent Director and Audit Committee Chair
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio Appoints Bethany Mancilla as Chief Business Officer
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 Disease
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio Announces IND Clearance of LTS-101 for CLN2 Disease and Receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio Launches AI/ML Strategy to Transform AAV Gene Therapy, Adds Two Leading Experts in Peptide and Protein Modeling to Scientific Advisory Board
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
From Latus Bio, Inc.
Via Business Wire
News headline image
Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing
From Latus Bio, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.